After announcing its intent to liquidate on August 30, Crixus BH3 Acquisition Company (NASDAQ:BHAC) disclosed this afternoon that it has reversed its decision to dissolve its trust.
Crixus BH3’s board determined that it is in the best interest of the company and its stockholders to continue its pursuit of a target to combine with.
For the time being, the sponsor, Crixus BH3 Sponsor LLC, has extended the completion deadline to October 6 and deposited $175,440.72 into the trust account to fund any redemption of the offering shares.
As a result of the change in plans, the company will not redeem its offering shares and will proceed with its special meeting, which has been rescheduled to September 29. At the meeting, the SPAC is hoping to gain shareholder approval to extend the completion deadline from March 31, 2024, to July 31, 2024.
With a current termination date in October, this would provide the company with an additional nine months to find a target to combine with. Crixus BH3 originally set out to focus its efforts on businesses that manage, finance, operate, construct, control, own or support real estate. It raised a total of $232.3 million in gross proceeds from its IPO in October 2021, but is currently left with $52.9 million in its trust.
And, interestingly enough, Crixus BH3’s choice to reverse its liquidation comes on the heels of Atlantic Coastal Acquisition Corp.‘s (NASDAQ:ACAH) decision to do the same. ACAH, which announced last week that it intended to liquidate, opted to reverse that decision and will now hold an extension vote on September 8th.
Crixus BH3 is led by Co-CEO Daniel Lebensohn, Co-CEO and CFO Gregory Freedman, and COO Michelle Guber.
D. Boral ARC Acquisition II Corp. (NASDAQ:ARBCU) has filed for a $250 million SPAC to give underwriter D. Boral a second in-house SPAC to pursue deals with. The new SPAC offers investors a 1/2 warrant and an initial 18-month time frame to complete a deal. D. Boral II’s sponsor may automatically extend this once by...
Ribbon (NASDAQ:RIBB) has entered into a definitive agreement to combine with Japanese biotech firm DRC Medicine at a pro forma equity value of $422 million. Tokyo-based DRC Medicine manufactures reusable anti-bacterial and anti-allergen wearables and aims to go deeper into the medical device and pharmaceutical space. Transaction Overview Ribbon is expected to provide $50.4 million...
In June 2025, the SPAC market was marked by a notable rise in meeting delays, with adjournments and postponements playing a central role in extension activity, as sponsors navigated a more cautious market environment. Still, several SPACs secured shareholder approvals, and seven business combinations were completed during the month. At the same time, IPO issuance...
An In-Depth Look at SPAC Activity Through the Second Quarter & First Half 2025 Below is a summary of the first half of 2025 SPAC market. If you’d like a pdf copy, you can access the link HERE. Q2 kicked off in chaos. President Trump’s shifting and often contradictory tariff announcements sent markets reeling, driving...
At the SPAC of Dawn The market is set to be showered with new SPACs today as three more SPACs priced their IPOs overnight, bringing 2025’s total to 66, already surpassing the full-year total of 2024. After hours, Ribbon (NASDAQ:RIBB) also added a new SPAC deal to June’s tally just under the wire, bringing the...